Annals of Oncology 14:1012-1013, 2003
© 2003 European Society for Medical Oncology
Original Paper |
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cutaneous malignant melanoma
Oncology, Medical University Clinic, Kantonsspital, Bruderholz, Switzerland
| The first 10% of the full text of this article appears below. |
 |
Incidence |
|---|
- The crude incidence of malignant melanoma in the European Union is 9 cases/100 000 per year. The incidence increases with latitude, i.e. with increasing prevalence of less-pigmented skin types, from 3–5 cases/100 000 per year in Mediterranean countries to 12–17/100 000 per year in Nordic countries. The mortality is 2.3 cases/100 000 per year with a lesser variation with geography. Increased ultraviolet B-ray exposure seems responsible for an ongoing increase in incidence during recent decades.
|
Diagnosis |
|---|
- Suspicious lesions are characterized by asymmetry, border irregularities, color heterogeneity, diameter >6 mm, and evolution of color, elevation or
. . . [Full Text of this Article]
|
Staging and risk assessment |
|---|
|
Treatment for localized disease |
|---|
|
Treatment for locoregional metastatic disease |
|---|
|
Treatment for systemic metastatic disease |
|---|
|
Follow-up for localized or locoregional disease |
|---|
|
Note |
|---|
|
Literature |
|---|
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Z. Belhocine, A. M. Scott, E. Even-Sapir, J.-L. Urbain, and R. Essner Role of Nuclear Medicine in the Management of Cutaneous Malignant Melanoma J. Nucl. Med., June 1, 2006; 47(6): 957 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ludwig A Foundation for the future Ann. Onc., January 1, 2005; 16(1): 3 - 3. [Full Text] [PDF]
|
|
|
|
|
|
H. Ludwig European Society of Medical Oncology membership survey Ann. Onc., February 1, 2004; 15(2): 181 - 182. [Full Text] [PDF]
|
|